首页 正文

Cost-Effectiveness Analysis of Crizanlizumab in Sickle Cell Disease in Iran

{{output}}
Background: Sickle cell disease (SCD) prevalence is predicted to rise dramatically in the upcoming years. Although several medications have received Food and Drug Administration (FDA) approval in recent years, low- and middle-inc... ...